Abbott Receives the US FDA and EU Approvals for Ablation Technologies to Treat Abnormal Heart Rhythms
- Abbott’s FlexAbility sensor enabled ablation catheter received the US FDA approval for a new indication. The device is now approved as a treatment option for ventricular tachycardia (VT) in patients with non-ischemic cardiomyopathy
- The decision was based on the (LESS-VT) study in 600 adult patients who were randomized to either undergo treatment with a previously approved ablation device or the FlexAbility SE Ablation Catheter which showed that 80% of patients treated with the FlexAbility device were free from VT for 6mos. after the procedure & improvements were seen in overall mental & physical health
- TactiFlex sensor enabled ablation catheter received CE Mark approval for arrhythmias i.e., AFib & is now available in EU, Africa, Japan & Australia
Ref: Abbott | Image: Abbott
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.